NASDAQ:SGEN
Delisted
Seattle Genetics Stock News
$228.74
+0 (+0%)
At Close: Mar 12, 2024
Will Seattle Genetics (SGEN) Report Negative Earnings Next Week? What You Should Know
01:33pm, Thursday, 22'nd Apr 2021
Seattle Genetics (SGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Seagen's (SGEN) Two sBLAs for Padcev Gets FDA Priority Review
11:17am, Tuesday, 20'th Apr 2021
The FDA accepts Seagen (SGEN) and Astellas' two sBLAs for Padcev under a priority review to treat patients with locally advanced or metastatic urothelial carcinoma. A verdict is pending on Aug 17, 202
TOKYO and BOTHELL, Wash., April 19, 2021 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D.
Seagen's (SGEN) Tisotumab Vedotin BLA Gets FDA Priority Review
09:51am, Monday, 12'th Apr 2021
The FDA accepts Seagen (SGEN) and Genmab's BLA for tisotumab vedotin under a priority review to treat recurrent/metastatic cervical cancer. A verdict is pending on Oct 10, 2021.
Seagen: The New Oncology Hope
04:09am, Monday, 12'th Apr 2021
In recent years, Seagen has undergone a transformation from a one-product company to a diversified player in the oncology drug market. The current conservative stock price based on the DCF model is $
Does 2021's Best Biopharma to Work for Belong in Your Portfolio?
06:10am, Wednesday, 07'th Apr 2021
Horizon Therapeutics has a clear path to significant sales growth.
Seagen's (SGEN) MAA for Enfortumab Vedotin Gets EMA Acceptance
10:36am, Monday, 29'th Mar 2021
The European Medicines Agency accepts Seagen (SGEN) and Astellas Pharma's marketing application for enfortumab vedotin for treating adult patients with advanced/metastatic urothelial cancer.
European Medicines Agency Accepts Marketing Authorization Application for Enfortumab Vedotin
02:00am, Friday, 26'th Mar 2021
TOKYO & BOTHELL, Wash.--(BUSINESS WIRE)--Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seagen Inc. (Nasdaq:SGEN) today announced that a marketing autho
Moving Average Crossover Alert: Seagen
07:11am, Monday, 15'th Mar 2021
Seagen (SGEN) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
Seattle Genetics (SGEN) Down 12.4% Since Last Earnings Report: Can It Rebound?
12:08pm, Saturday, 13'th Mar 2021
Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock?
7 Biotech Stocks With Catalysts That Go Far Beyond Covid-19 Vaccines
11:54am, Friday, 12'th Mar 2021
If you think ecommerce and digital banking have accelerated in the past year, then you really need to check out promising biotech stocks. The post 7 Biotech Stocks With Catalysts That Go Far Beyond Co
Seagen Recommends Rejection Of 'Mini-Tender' Offer from TRC Capital Investment Corporation
08:00am, Friday, 05'th Mar 2021
BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) today announced that it has been notified of an unsolicited “mini-tender” offer dated February 22, 2021, made by TRC Capital Investment C
Seagen (SGEN), Astellas Submit 2 sBLAs to FDA for Urothelial Cancer
12:07pm, Friday, 19'th Feb 2021
Seagen (SGEN) and Astellas Pharma announced completion of submissions of two sBLAs to the FDA for Padcev in patients with locally advanced or metastatic urothelial carcinoma.
BOTHELL, Wash. & TOKYO--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced completion of submissi
BOTHELL, Wash. & TOKYO--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced results from the secon
